Sutro Biopharma Stock Price, News & Analysis (NASDAQ:STRO) $2.87 +0.12 (+4.36%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$2.69▼$2.8850-Day Range$2.07▼$3.9852-Week Range$2.01▼$8.72Volume567,596 shsAverage Volume522,511 shsMarket Capitalization$174.93 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Sutro Biopharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside387.8% Upside$14.00 Price TargetShort InterestHealthy3.77% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.97Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.03) to ($3.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.76 out of 5 starsMedical Sector68th out of 952 stocksBiological Products, Except Diagnostic Industry10th out of 155 stocks 4.4 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Sutro Biopharma has a forecasted upside of 387.8% from its current price of $2.87.Amount of Analyst CoverageSutro Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.77% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 2.95%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sutro Biopharma is -0.70. Previous Next 2.8 News and Social Media Coverage News SentimentSutro Biopharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sutro Biopharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions89.40% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to decrease in the coming year, from ($3.03) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sutro Biopharma Stock (NASDAQ:STRO)Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More STRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STRO Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comSutro Biopharma to Participate in the JMP Securities Hematology and Oncology SummitDecember 1, 2023 | seekingalpha.comAbbVie-ImmunoGen buyout deal lifts ADC-focused biotechsDecember 4, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 1, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: G1 Therapeutics (GTHX), Sutro Biopharma (STRO)November 27, 2023 | markets.businessinsider.comVaxcyte Obtains Control Over Manufacturing & Development Of Cell-Free Extract For Vaccine CandidatesNovember 27, 2023 | finance.yahoo.comVaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNovember 23, 2023 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Promotes Jane Chung to President and Chief Operating OfficerNovember 21, 2023 | finance.yahoo.comSutro Biopharma Promotes Jane Chung to President and Chief Operating OfficerDecember 4, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 16, 2023 | markets.businessinsider.comOptimistic Outlook on Sutro Biopharma: Solid Financials, Promising Drug Pipeline, and High Return Potential Fuel Buy RatingNovember 15, 2023 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesNovember 15, 2023 | markets.businessinsider.comExpert Ratings for Sutro BiopharmaNovember 13, 2023 | finance.yahoo.comSutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesNovember 13, 2023 | finance.yahoo.comSutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business UpdatesNovember 11, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sutro Biopharma, Inc. (NASDAQ: STRO) and Encourages Investors to Contact the FirmNovember 9, 2023 | msn.comDeutsche Bank Initiates Coverage of Sutro Biopharma (STRO) with Buy RecommendationNovember 8, 2023 | news.yahoo.comSutro introduces AI-powered app creation with no coding requiredNovember 6, 2023 | morningstar.comSutro Biopharma Inc STRONovember 4, 2023 | finance.yahoo.comSutro Biopharma (NASDAQ:STRO) shareholders are up 11% this past week, but still in the red over the last three yearsOctober 25, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Sutro Biopharma (STRO)October 24, 2023 | markets.businessinsider.comPromising Clinical Trials and Robust Financial Health Drive Buy Rating for Sutro BiopharmaOctober 24, 2023 | msn.comWedbush Reiterates Sutro Biopharma (STRO) Outperform RecommendationOctober 22, 2023 | finance.yahoo.comSutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023October 16, 2023 | finance.yahoo.comSutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC ConferenceOctober 7, 2023 | msn.comOppenheimer Initiates Coverage of Sutro Biopharma (STRO) with Outperform RecommendationOctober 6, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Sutro BiopharmaOctober 1, 2023 | barrons.comSutro Biopharma Inc.See More Headlines Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees298Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$25.00 Low Stock Price Target$8.00 Potential Upside/Downside+387.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,200,000.00 Net Margins-354.53% Pretax Margin-349.63% Return on Equity-99.73% Return on Assets-40.19% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.18 Sales & Book Value Annual Sales$67.77 million Price / Sales2.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.78 per share Price / Book0.76Miscellaneous Outstanding Shares60,950,000Free Float56,747,000Market Cap$174.93 million OptionableNot Optionable Beta0.86 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. William J. Newell J.D. (Age 65)CEO & Director Comp: $1.07MMs. Jane Chung R.Ph. (Age 52)Chief Commercial Officer Comp: $934.64kDr. James R. Swartz Ph.D.Sc.D., FounderMr. Edward C. Albini (Age 65)CFO & Secretary Comp: $596.4kDr. Venkatesh Srinivasan Ph.d.Chief Technical Operations OfficerDr. Hans-Peter Gerber Ph.D.Chief Scientific OfficerMr. David Pauling J.D.M.A., General CounselMs. Linda A. Fitzpatrick (Age 66)Chief People & Communications Officer Comp: $595.79kDr. Nicki Vasquez Ph.D. (Age 60)Chief Portfolio Strategy & Alliance Officer Ms. Brunilda Shtylla M.B.A. (Age 49)M.S., Chief Business Officer More ExecutivesKey CompetitorsKodiak SciencesNASDAQ:KODOptheaNASDAQ:OPTAcumen PharmaceuticalsNASDAQ:ABOSX4 PharmaceuticalsNASDAQ:XFORMonte Rosa TherapeuticsNASDAQ:GLUEView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 8,711 shares on 11/30/2023Ownership: 0.061%Deutsche Bank AGBought 5,848 shares on 11/24/2023Ownership: 0.055%Jacobs Levy Equity Management Inc.Sold 145,702 shares on 11/17/2023Ownership: 0.698%Sectoral Asset Management Inc.Bought 31,693 shares on 11/15/2023Ownership: 0.715%Ameriprise Financial Inc.Sold 20,016 shares on 11/15/2023Ownership: 0.175%View All Insider TransactionsView All Institutional Transactions STRO Stock Analysis - Frequently Asked Questions Should I buy or sell Sutro Biopharma stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STRO shares. View STRO analyst ratings or view top-rated stocks. What is Sutro Biopharma's stock price target for 2024? 8 brokers have issued 1-year price objectives for Sutro Biopharma's stock. Their STRO share price targets range from $8.00 to $25.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 387.8% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts. How have STRO shares performed in 2023? Sutro Biopharma's stock was trading at $8.08 on January 1st, 2023. Since then, STRO shares have decreased by 64.5% and is now trading at $2.87. View the best growth stocks for 2023 here. When is Sutro Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our STRO earnings forecast. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) announced its earnings results on Monday, November, 13th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. Sutro Biopharma had a negative net margin of 354.53% and a negative trailing twelve-month return on equity of 99.73%. What ETF holds Sutro Biopharma's stock ? Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio. What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV). When did Sutro Biopharma IPO? (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (5.53%), Adage Capital Partners GP L.L.C. (5.13%), Kynam Capital Management LP (2.57%), Acadian Asset Management LLC (1.28%), Vontobel Holding Ltd. (0.74%) and Sectoral Asset Management Inc. (0.71%). Insiders that own company stock include Brunilda Shtylla, Nicki Vasquez, Trevor Hallam and William J Newell. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:STRO) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.